Heidi Chen

发表

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.

William Pao, John D. Minna, Yu Shyr, 2014, JAMA.

Shared gene expression profiles in individuals with autoimmune disease and unaffected first-degree relatives of individuals with autoimmune disease.

Yu Shyr, N. Olsen, T. Aune, 2005, Human molecular genetics.

Assessing the inter-observer variability of Computer-Aided Nodule Assessment and Risk Yield (CANARY) to characterize lung adenocarcinomas

Tucker F Johnson, Srinivasan Rajagopalan, Sanja L Antic, 2018, PloS one.

Identification of Proteomic Features To Distinguish Benign Pulmonary Nodules from Lung Adenocarcinoma.

Lisa J Zimmerman, Pierre P Massion, Daniel C Liebler, 2017, Journal of proteome research.

EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.

Jens Meiler, Taofeek K Owonikoko, Jonathan H Sheehan, 2016, Cancer discovery.

Characterizing Tumor Response to Chemotherapy at Various Length Scales Using Temporal Diffusion Spectroscopy

Ping Zhao, John C. Gore, Mark D. Does, 2012, PloS one.

Acyl-Coenzyme A–Binding Protein Regulates Beta-Oxidation Required for Growth and Survival of Non–Small Cell Lung Cancer

Pierre P Massion, Richard M Caprioli, Jun Qian, 2014, Cancer Prevention Research.

Rationale for co-targeting IGF-1R and ALK in ALK fusion positive lung cancer

William Pao, Zhongming Zhao, Ronglai Shen, 2014, Nature Medicine.

DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): A Catalog of Clinically Relevant Cancer Mutations to Enable Genome-Directed Anticancer Therapy

William Pao, Paul Yeh, Riyad Naser, 2013, Clinical Cancer Research.